JP2005500300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500300A5 JP2005500300A5 JP2003506277A JP2003506277A JP2005500300A5 JP 2005500300 A5 JP2005500300 A5 JP 2005500300A5 JP 2003506277 A JP2003506277 A JP 2003506277A JP 2003506277 A JP2003506277 A JP 2003506277A JP 2005500300 A5 JP2005500300 A5 JP 2005500300A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- preparation
- compound
- treatment
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 4
- 150000002596 lactones Chemical class 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- 125000001033 ether group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- ZGLXUQQMLLIKAN-SVIJTADQSA-N Anthricin Natural products COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-SVIJTADQSA-N 0.000 claims 2
- 102000003746 Insulin Receptor Human genes 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000036823 Plasma Levels Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 claims 2
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 102100014231 IGF1 Human genes 0.000 claims 1
- 101700074337 IGF1 Proteins 0.000 claims 1
- 102100014263 IGF1R Human genes 0.000 claims 1
- 101700025802 IGF1R Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000000865 phosphorylative Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
Claims (20)
- ピクロポドフィリンである、請求項1または2に記載の化合物。
- 生理学的に許容される担体と組み合わせて、請求項1〜3のいずれか1項に記載の化合物を含む、薬学的組成物。
- ピクロポドフィリン(picropodophyllin)およびデオキシピクロポドフィリン(deoxypicropodophyllin)からなる群より選択される、請求項5〜7のいずれかに記載の使用。
- β−アポピクロポドフィリンおよびα−アポピクロポドフィリンからなる群より選択される化合物の請求項5、6および9のいずれかに記載の使用。
- 癌の予防または処置のための医薬の調製のための、請求項5〜10のいずれかに記載の使用。
- 悪性黒色腫、ユーイング肉腫、乳癌もしくは前立腺癌の予防または処置のための医薬の調製のための、請求項5〜11のいずれか1項に記載の使用。
- 白血病の予防または処置のための医薬の調製のための、請求項5〜11のいずれか1項に記載の使用。
- 癌の処置のための医薬の調製のための、細胞増殖抑制剤(cytostaticum)と組み合わせた、式Iの化合物の請求項5〜10のいずれか1項に記載の使用。
- 乾癬の予防または処置のための医薬の調製のための、請求項5〜10のいずれか1項に記載の使用。
- 動脈硬化症の予防または処置のための医薬の調製のための、請求項5〜10のいずれか1項に記載の使用。
- 冠動脈血管形成後の再狭窄の予防または処置のための医薬の調製のための、請求項5〜10のいずれか1項に記載の使用。
- 先端巨大症の予防または処置のための医薬の調製のための、請求項5〜10のいずれか1項に記載の使用。
- 0.05〜5.0μMの濃度でその血漿レベルを維持するために有効な量の化合物を含む、癌の処置のための医薬の調製のための、請求項1〜10のいずれかに記載の化合物の使用。
- 哺乳動物における癌の処置の方法であって、該方法は、腫瘍に罹患する患者への持続注入によって、生理学的に許容される担体と組み合わせて、式Iを有する化合物を含む薬学的組成物を投与する工程、該化合物の血漿レベルを制御する工程、および腫瘍が遅延するかまたは消滅するのに十分な期間、0.05〜5.0μMの濃度で血漿レベルを維持するために注入速度を調整する工程を包含する。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102168-2 | 2001-06-19 | ||
SE0102168A SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | New use and new compounds |
US30043101P | 2001-06-26 | 2001-06-26 | |
US60/300,431 | 2001-06-26 | ||
PCT/SE2002/001202 WO2002102804A1 (en) | 2001-06-19 | 2002-06-19 | New use of specific cyclolignans |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009134006A Division JP2009242406A (ja) | 2001-06-19 | 2009-06-03 | 特定のシクロリグナン類の新しい使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005500300A JP2005500300A (ja) | 2005-01-06 |
JP2005500300A5 true JP2005500300A5 (ja) | 2006-01-05 |
JP5071910B2 JP5071910B2 (ja) | 2012-11-14 |
Family
ID=20284528
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003506277A Expired - Fee Related JP5071910B2 (ja) | 2001-06-19 | 2002-06-19 | 特定のシクロリグナン類の新しい使用 |
JP2003506278A Pending JP2004534078A (ja) | 2001-06-19 | 2002-06-19 | シクロリグナン類の新規の使用および新規のシクロリグナン類 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003506278A Pending JP2004534078A (ja) | 2001-06-19 | 2002-06-19 | シクロリグナン類の新規の使用および新規のシクロリグナン類 |
Country Status (15)
Country | Link |
---|---|
US (7) | US7348358B2 (ja) |
EP (5) | EP1938819A3 (ja) |
JP (2) | JP5071910B2 (ja) |
KR (1) | KR100940055B1 (ja) |
CN (3) | CN1659171A (ja) |
AT (1) | ATE441411T1 (ja) |
AU (2) | AU2002311731B8 (ja) |
CA (2) | CA2455328C (ja) |
DK (1) | DK1498121T3 (ja) |
ES (1) | ES2333014T3 (ja) |
NO (1) | NO332642B1 (ja) |
NZ (2) | NZ530172A (ja) |
PT (1) | PT1498121E (ja) |
SE (1) | SE0102168D0 (ja) |
WO (2) | WO2002102805A1 (ja) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
SE0203746D0 (sv) * | 2002-12-18 | 2002-12-18 | Karolinska Innovations Ab | New compounds |
SE0203747D0 (sv) * | 2002-12-18 | 2002-12-18 | Karolinska Innovations Ab | New use |
SE0301202D0 (sv) * | 2003-04-24 | 2003-04-24 | Orteca Ab C O Karolinska Innov | New use and new compounds |
US7342114B2 (en) | 2003-07-01 | 2008-03-11 | California Pacific Medical Center | Podophyllotoxin derivatives |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
TW200530238A (en) * | 2003-10-15 | 2005-09-16 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
US7781393B2 (en) | 2004-02-25 | 2010-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting tumor cell growth |
DK1732898T3 (da) | 2004-03-12 | 2008-05-13 | Analytecon Sa | Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R |
UA89493C2 (uk) | 2004-04-02 | 2010-02-10 | Оси Фармасьютикалз, Инк. | 6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP1991218A4 (en) * | 2006-02-24 | 2010-11-03 | Axelar Ab | USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES |
US20080085874A1 (en) * | 2006-08-28 | 2008-04-10 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
WO2009100349A1 (en) | 2008-02-09 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Analogues of (-)-picropodophyllin, synthesis and uses thereof |
WO2009108857A2 (en) * | 2008-02-27 | 2009-09-03 | Combithera, Inc. | Combination therapy for prostate cancer |
CA2723648A1 (en) * | 2008-04-10 | 2009-10-15 | Piyush Gupta | Methods for identification and use of agents targeting cancer stem cells |
WO2009143051A1 (en) * | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
MX2011004824A (es) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2421837A1 (en) | 2009-04-20 | 2012-02-29 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
WO2010138686A1 (en) * | 2009-05-29 | 2010-12-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mdri-inverse agents |
US7924203B2 (en) * | 2009-06-12 | 2011-04-12 | Analog Devices, Inc. | Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CA2809003C (en) | 2010-08-31 | 2018-07-17 | Axelar Ab | Process for preparing cyclolignans |
JP2013538872A (ja) | 2010-10-08 | 2013-10-17 | アクセラー・アーベー | 癌治療における使用のためのピクロポドフィリン多形体b又はc |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
JP5892508B2 (ja) * | 2011-05-23 | 2016-03-23 | 国立大学法人 鹿児島大学 | 抗腫瘍剤及びその製造方法 |
WO2013124382A1 (en) * | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of cardiovascular disorders |
WO2013132262A1 (en) | 2012-03-09 | 2013-09-12 | Axelar Ab | Picropodophyllin derivatives |
WO2013132263A1 (en) | 2012-03-09 | 2013-09-12 | Axelar Ab | Picropodophyllin derivatives for use in therapy |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Cgrp応答性促進剤 |
WO2014102889A1 (ja) * | 2012-12-25 | 2014-07-03 | 国立大学法人鹿児島大学 | 抗腫瘍剤及びその製造方法 |
JP6255038B2 (ja) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス,インク. | 癌治療 |
US9907783B2 (en) | 2013-05-10 | 2018-03-06 | m.Alphabet 2, LLC | Methods of treating skin conditions using cyclolignan compounds |
WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
CN104434909A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途 |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
US10087194B2 (en) | 2015-10-27 | 2018-10-02 | California Pacific Medical Center | Podophyllotoxin derivatives and their use |
CN106937529B (zh) | 2015-10-27 | 2021-02-05 | 加州太平洋医疗中心 | 鬼臼毒素衍生物及其应用 |
CN110669054B (zh) * | 2018-07-03 | 2022-04-26 | 南京药石科技股份有限公司 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
KR102378151B1 (ko) * | 2020-05-11 | 2022-03-24 | 주식회사 제이앤씨사이언스 | 베타-아포피크로포도필린의 신규한 유도체 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2825730A (en) * | 1953-02-04 | 1958-03-04 | Thompson Boyce Plant Res | Organic compounds |
US4342777A (en) * | 1979-03-29 | 1982-08-03 | The United States Of America As Represented By The Secretary Of Agriculture | Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control |
WO1986004062A1 (en) | 1984-12-28 | 1986-07-17 | Conpharm Ab | Pharmaceutically active compound and a method for its preparation |
US4771072A (en) * | 1985-01-10 | 1988-09-13 | Tanabe Seiyaku Co., Ltd. | Alkoxynaphthalene derivatives |
SE468213B (sv) * | 1986-06-27 | 1992-11-23 | Conpharm Ab | Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit |
EP0289506A4 (en) * | 1986-11-19 | 1990-12-12 | Chemex Pharmaceuticals, Inc. | Lipoxygenase inhibitors |
SE464167B (sv) * | 1989-07-31 | 1991-03-18 | Analytecon Sa | Topisk farmaceutisk beredning av podophyllotoxin |
CN1075316A (zh) | 1992-10-22 | 1993-08-18 | 布里斯托尔-米尔斯·斯奎布公司 | 表鬼臼毒中间体的制备方法 |
GB9422947D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Immunosuppressive cyclolignan derivatives |
JPH09194368A (ja) * | 1996-01-11 | 1997-07-29 | Pola Chem Ind Inc | ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤 |
US5726027A (en) | 1996-03-08 | 1998-03-10 | The Regents Of The University Of California | Method for treatment of insulin resistance |
WO1999028347A1 (en) | 1997-11-27 | 1999-06-10 | Commonwealth Scientific And Industrial Research Organisation | Method of designing agonists and antagonists to igf receptor |
DE69900689T2 (de) | 1998-06-26 | 2002-08-29 | Quanam Medical Corp | Topoisomerase inhibitoren zur restenose-prevention |
EP1251858B1 (en) | 2000-01-20 | 2005-06-08 | Supratek Pharma Inc. | Podophyllotoxin compositions |
JP4024148B2 (ja) * | 2000-11-20 | 2007-12-19 | ソンベ キム | 新規な4’−デメチル−4’−o−置換−1−デオキシポドフィロトキシン誘導体及びその幾何異性体、その製造方法及びそれを含んでなる抗癌剤組成物 |
SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
US7714139B2 (en) * | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
SE0301202D0 (sv) * | 2003-04-24 | 2003-04-24 | Orteca Ab C O Karolinska Innov | New use and new compounds |
-
2001
- 2001-06-19 SE SE0102168A patent/SE0102168D0/xx unknown
-
2002
- 2002-06-19 JP JP2003506277A patent/JP5071910B2/ja not_active Expired - Fee Related
- 2002-06-19 EP EP08150437A patent/EP1938819A3/en not_active Withdrawn
- 2002-06-19 JP JP2003506278A patent/JP2004534078A/ja active Pending
- 2002-06-19 NO NO20035648A patent/NO332642B1/no not_active IP Right Cessation
- 2002-06-19 PT PT04024370T patent/PT1498121E/pt unknown
- 2002-06-19 CA CA2455328A patent/CA2455328C/en not_active Expired - Fee Related
- 2002-06-19 CA CA2451047A patent/CA2451047C/en not_active Expired - Fee Related
- 2002-06-19 US US10/481,441 patent/US7348358B2/en not_active Expired - Fee Related
- 2002-06-19 EP EP02741588A patent/EP1397369A1/en not_active Ceased
- 2002-06-19 EP EP04024370A patent/EP1498121B1/en not_active Expired - Lifetime
- 2002-06-19 KR KR1020037016630A patent/KR100940055B1/ko active IP Right Grant
- 2002-06-19 NZ NZ53017202A patent/NZ530172A/xx unknown
- 2002-06-19 WO PCT/SE2002/001223 patent/WO2002102805A1/en not_active Application Discontinuation
- 2002-06-19 CN CN028162404A patent/CN1659171A/zh active Pending
- 2002-06-19 EP EP10153209A patent/EP2186513A1/en not_active Withdrawn
- 2002-06-19 WO PCT/SE2002/001202 patent/WO2002102804A1/en active IP Right Grant
- 2002-06-19 US US10/480,800 patent/US20040167208A1/en not_active Abandoned
- 2002-06-19 AT AT04024370T patent/ATE441411T1/de active
- 2002-06-19 EP EP08150436A patent/EP1938818A3/en not_active Withdrawn
- 2002-06-19 ES ES04024370T patent/ES2333014T3/es not_active Expired - Lifetime
- 2002-06-19 AU AU2002311731A patent/AU2002311731B8/en not_active Ceased
- 2002-06-19 AU AU2002314671A patent/AU2002314671B2/en not_active Ceased
- 2002-06-19 NZ NZ530290A patent/NZ530290A/en not_active IP Right Cessation
- 2002-06-19 DK DK04024370T patent/DK1498121T3/da active
- 2002-06-19 CN CNA2009101347598A patent/CN101606929A/zh active Pending
- 2002-06-19 CN CNB028161904A patent/CN100503611C/zh not_active Expired - Fee Related
-
2006
- 2006-02-03 US US11/346,294 patent/US7709526B2/en not_active Expired - Fee Related
-
2008
- 2008-01-29 US US12/021,530 patent/US7629381B2/en not_active Expired - Fee Related
- 2008-01-29 US US12/021,578 patent/US7662851B2/en not_active Expired - Fee Related
-
2009
- 2009-07-23 US US12/508,218 patent/US8389747B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 US US12/714,107 patent/US20100216728A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005500300A5 (ja) | ||
CA2451047A1 (en) | Use of picropodophyllin derivatives for treatment of igf-1r mediated disorders | |
FI111808B (fi) | Menetelmä uusien, taksaaneihin perustuvien farmaseuttisten koostumusten valmistamiseksi | |
CN1047305C (zh) | 可注射的组合物 | |
EA021757B1 (ru) | Фармацевтические комбинации, содержащий их набор, применение этих комбинаций и способ лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
JP2001247459A (ja) | 癌の組み合わせ療法 | |
JP2009513662A5 (ja) | ||
JP2011509309A5 (ja) | ||
JP2012062329A (ja) | 併用化学療法 | |
JP2004517843A5 (ja) | ||
EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
JP2003525239A (ja) | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
EP3922251A1 (en) | Cancer immunotheraphy adjuvant | |
JP2004525140A5 (ja) | ||
JP2004517882A (ja) | トリプトライドプロドラッグを使用する抗癌処置 | |
JP2010540649A5 (ja) | ||
RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
JP2006510658A5 (ja) | ||
US6689811B2 (en) | Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers | |
RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
CN1897949A (zh) | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 | |
Bouchard et al. | Novel taxanes: cabazitaxel case study | |
JPH02501930A (ja) | 薬学的化合物のための新規な用途 | |
KR100330373B1 (ko) | 탁솔을 함유한 주사용 약제 조성물 | |
JP2004536857A5 (ja) |